Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes [clinicaltrials:NCT00451997]

Bio2RDF identifier

NCT00451997

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00451997

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00451997

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

10

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00451997 arm group ef50968052f0ee444aee4898e5129372 [clinicaltrials_resource:NCT00451997/arm-group/ef50968052f0ee444aee4898e5129372]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ca1954f55de6b13c270f49787460e895

brief summary [clinicaltrials_vocabulary:brief-summary]

The goal of this clinic ...... ndard high dose chemotherapy.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:35a113dfc414e1691041e00d56fd6670]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:2126b67b54910ee085351b625b504918]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:29e585631c4d5464295fc46d3dbfdcab]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:5b92db64a60ba1be30947bebaaf979ed]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:7be1cfed15212dd7e3b4d5da1a8b3ed4]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:89e9ea2e69ae9b8a346669556ec7fcff]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:d63f32cd962dfa7f17e9a1c2cf93f0d4]

Efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression. April 2007 [clinicaltrials_resource:ec99aa2258a7ca54aabc3f87512e71d5]

collaborator [clinicaltrials_vocabulary:collaborator]

M.D. Anderson Cancer Center [clinicaltrials_resource:6f414a642fffdb8268f5874fbb382ccc]

completion date [clinicaltrials_vocabulary:completion-date]

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Imatinib mesylate is a ...... nib and low-dose ara-C.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00451997 [clinicaltrials_resource:08a38e3ee9fa4a2d044a0421f9d924d4]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Gleevec [clinicaltrials_resource:3557298df3c280053f3abcbe81562a00]

Ara-C [clinicaltrials_resource:ec0a47c37787502897b889c7d36f9b97]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Cytarabine [clinicaltrials_resource:22c1374b2123aed8146827c85013eca8]

Imatinib [clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

AML

http://www.w3.org/2001/XMLSchema#string

Ara-C

http://www.w3.org/2001/XMLSchema#string

C-Kit Positive Acute Myeloid Leukemia

http://www.w3.org/2001/XMLSchema#string

Gleevec

http://www.w3.org/2001/XMLSchema#string

High-Risk Myelodysplastic Syndromes

http://www.w3.org/2001/XMLSchema#string

MDS

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

M.D. Anderson Cancer Center [clinicaltrials_resource:6f414a642fffdb8268f5874fbb382ccc]

link [clinicaltrials_vocabulary:link]

M.D. Anderson's Website [clinicaltrials_resource:ef87e7ef19a7059afc26af3765621cd2]

location [clinicaltrials_vocabulary:location]

The University of Texas M.D. Anderson Cancer Center [clinicaltrials_resource:33b12a780830038c4973e9742de9c868]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00451997

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Phase II Trial of Gleevec and ...... Risk Myelodysplastic Syndromes

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2003-0935

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Jorge E Cortes, MD [clinicaltrials_resource:e993e45aa06a27c7ccfccbac4c3d3897]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:b46c5f1ee626ee51e33e6c048a7b19f6]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

M.D. Anderson Cancer Center [clinicaltrials_resource:6f414a642fffdb8268f5874fbb382ccc]

start date [clinicaltrials_vocabulary:start-date]

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00451997 study design [clinicaltrials_resource:752d0b147b8cad5006adb579c183afd6]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00451997

verification date [clinicaltrials_vocabulary:verification-date]

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00451997

http://www.w3.org/2001/XMLSchema#string

title

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]